Complete News, Your Way.
Get Started
SubscribeLogin
Mother's Day
Real Madrid
Motorsports
Vladimir Putin
Israel-Hamas Conflict
Soccer
Pope Francis
Social Media
Premier League
Donald Trump
Natural Disasters
Manchester United
Published • loading... • Updated

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)

Summary by Ground News
Merck KGaA regains exclusive rights to develop, manufacture, and commercialize Bavencio (avelumab) Pfizer will exit its global partnership over the PD-L1 MAb on 30 June. Pfizer shares are down 0.24% at $40.30 on the last check Monday.

3 Articles

All
Left
Center
1
Right
1
BenzingaBenzinga
Center

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)

·New York, United States
Read Full Article
HandelsblattHandelsblatt
Lean Right

Pharmaceutical industry: Pfizer returns rights to cancer immunotherapy Bavencio to Merck

Immunotherapy Bavencio was never able to fully meet these high expectations. Merck is now regaining full control over worldwide marketing.

·Düsseldorf, Germany
Read Full Article
wiwo.dewiwo.de

Pharmaceutical industry: Pfizer returns rights to cancer immunotherapy Bavencio to Merck

Immunotherapy has never been able to fully meet these high expectations. Merck is now regaining full control over worldwide marketing.

·Düsseldorf, Germany
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Handelsblatt broke the news in Düsseldorf, Germany on Monday, March 27, 2023.
Sources are mostly out of (0)

Similar News Topics

Economy

Economy

Pfizer

Pfizer

Merck

Merck

Germany

Germany

Germany Economy

Germany Economy

News
For You
SearchBlindspotLocal